New safety warnings for two classes of diabetes drugs: What pharmacists should know

Abstract

This spring, FDA called attention to two classes of diabetes drugsand potential serious risks associated with them. In April, theEndocrinologic and Metabolic Drugs Advisory Committee advisedFDA to add a heart failure warning to labels on dipeptidyl peptidase–4(DPP-4) inhibitors, also known as gliptins. A month later, FDA issueda drug safety communication warning that another diabetes drug,sodium–glucose linked transporter–2 (SGLT-2) inhibitors, could causeeuglycemic diabetic ketoacidosis.